Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting.

Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P.

PLoS One. 2014 Feb 12;9(2):e87872. doi: 10.1371/journal.pone.0087872. eCollection 2014.

PMID:
24533061
[PubMed - in process]
Free PMC Article
2.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P.

Lancet. 2010 Aug 14;376(9740):532-9. doi: 10.1016/S0140-6736(10)60936-1. Epub 2010 Jul 16.

PMID:
20638713
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
4.

Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.

Antivir Ther. 2004 Oct;9(5):713-9.

PMID:
15535408
[PubMed - indexed for MEDLINE]
5.

Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

Krentz HB, Kliewer G, Gill MJ.

HIV Med. 2005 Mar;6(2):99-106.

PMID:
15807715
[PubMed - indexed for MEDLINE]
6.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
[PubMed - indexed for MEDLINE]
7.
8.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
[PubMed - indexed for MEDLINE]
9.

Disparities in the burden of HIV/AIDS in Canada.

Hogg RS, Heath K, Lima VD, Nosyk B, Kanters S, Wood E, Kerr T, Montaner JS.

PLoS One. 2012;7(11):e47260. doi: 10.1371/journal.pone.0047260. Epub 2012 Nov 27.

PMID:
23209549
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.

Auvert B, Males S, Puren A, Taljaard D, Caraël M, Williams B.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):613-21.

PMID:
15097305
[PubMed - indexed for MEDLINE]
11.

Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.

Lima VD, Hogg RS, Montaner JS.

PLoS One. 2010 Jun 7;5(6):e10991. doi: 10.1371/journal.pone.0010991.

PMID:
20539817
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.

De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndèye GF, Sow PS, Ndèye KC, Ecochard R, Delaporte E; ANRS 1215 Study Group.

BMC Infect Dis. 2010 Jun 19;10:179. doi: 10.1186/1471-2334-10-179.

PMID:
20565900
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA.

BMC Health Serv Res. 2008 Nov 20;8:241. doi: 10.1186/1472-6963-8-241.

PMID:
19021908
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.

Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC).

Clin Infect Dis. 2007 Oct 1;45(7):918-24. Epub 2007 Aug 27.

PMID:
17806062
[PubMed - indexed for MEDLINE]
Free Article
15.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
[PubMed - indexed for MEDLINE]
Free Article
16.

When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.

Loubiere S, el Filal KM, Sodqi M, Loundou A, Luchini S, Cleary S, Moatti JP, Himmich H.

Antivir Ther. 2008;13(2):241-51.

PMID:
18505175
[PubMed - indexed for MEDLINE]
17.

Molecular biological assessment methods and understanding the course of the HIV infection.

Katzenstein TL.

APMIS Suppl. 2003;(114):1-37. Review.

PMID:
14626050
[PubMed - indexed for MEDLINE]
18.

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients.

Palella Jr FJ, Chmiel JS, Moorman AC, Holmberg SD; HIV Outpatient Study Investigators.

AIDS. 2002 Aug 16;16(12):1617-26.

PMID:
12172083
[PubMed - indexed for MEDLINE]
19.

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

Ann Intern Med. 2003 Nov 18;139(10):810-6.

PMID:
14623618
[PubMed - indexed for MEDLINE]
20.

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.

Ives NJ, Gazzard BG, Easterbrook PJ.

J Infect. 2001 Feb;42(2):134-9.

PMID:
11531320
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk